A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism

NCT07007793 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

250

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Hyperaldosteronism

Interventions

DRUG: Baxdrostat
DRUG: Placebo

Sponsor

AstraZeneca